Urispas

Urispas (flavoxate HCl) is a prescription antispasmodic medication specifically formulated to target and relieve symptoms associated with urinary tract conditions. It works by relaxing the smooth muscle of the urinary bladder, thereby reducing frequency, urgency, and painful spasms. Clinically proven and trusted by urologists, it provides targeted symptomatic relief for patients experiencing discomfort from various urologic diagnoses, improving quality of life and daily comfort.

Features

• Active ingredient: Flavoxate Hydrochloride 100 mg
• Prescription-only antispasmodic agent
• Tablet form for oral administration
• Musculotropic action with direct effect on detrusor muscle
• No anticholinergic activity at therapeutic doses
• Manufactured under strict pharmaceutical quality standards

Benefits

• Reduces urinary urgency and frequency, allowing for normalized voiding patterns
• Alleviates suprapubic pain and dysuria associated with bladder spasms
• Decreases nocturia, supporting uninterrupted sleep
• Improves overall comfort and daily functioning in patients with urologic conditions
• Provides targeted action with minimal effect on other smooth muscles
• Supports bladder rehabilitation and comfort during diagnostic procedures

Common use

Urispas is commonly prescribed for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence associated with urologic conditions such as cystitis, prostatitis, urethritis, and urethrocystitis/urethrotrigonitis. It is also used as adjunctive therapy following urologic surgical procedures and instrumentation to reduce bladder irritability.

Dosage and direction

The usual adult dosage is one 100 mg tablet three or four times daily. Dosage may be titrated upward to two tablets four times daily based on symptom severity and patient response. Tablets should be swallowed whole with a full glass of water, with or without food. For optimal results, administer at evenly spaced intervals throughout the waking hours. Do not crush or chew tablets. Duration of therapy is determined by the prescribing physician based on individual patient needs and response.

Precautions

Use with caution in patients with glaucoma, gastrointestinal obstruction, ileus, or severe ulcerative colitis. Elderly patients may be more sensitive to the effects of flavoxate. Patients should be cautioned about operating machinery or driving until their response to the medication is known. Periodic evaluation of continued need for therapy is recommended. Not recommended for use in children under 12 years of age due to insufficient safety data.

Contraindications

Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It is also contraindicated in patients with gastrointestinal hemorrhage, obstructive uropathy, intestinal atony, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, and myasthenia gravis.

Possible side effect

Common side effects may include nausea, vomiting, dry mouth, blurred vision, dizziness, drowsiness, headache, nervousness, and constipation. Less frequently reported effects include confusion (especially in elderly patients), tachycardia, palpitations, increased intraocular pressure, urticaria, and eosinophilia. Most side effects are dose-related and may diminish with continued therapy or dosage adjustment.

Drug interaction

No clinically significant drug interactions have been formally established. However, theoretical interactions may occur with other anticholinergic agents, potentially enhancing both therapeutic and adverse effects. Concurrent use with CNS depressants (alcohol, sedatives, tranquilizers) may enhance sedative effects. Monitor patients receiving MAO inhibitors or tricyclic antidepressants concurrently due to potential additive anticholinergic effects.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent therapeutic effect. If multiple doses are missed, contact healthcare provider for guidance on resuming therapy.

Overdose

Symptoms of overdose may include severe anticholinergic effects: dilated pupils, blurred vision, dry mouth, difficulty swallowing, hot dry skin, fever, tachycardia, hypertension, respiratory depression, and CNS disturbances including confusion, agitation, and hallucinations. Treatment is symptomatic and supportive. Gastric lavage may be beneficial if performed soon after ingestion. Activated charcoal may be administered. There is no specific antidote for flavoxate overdose.

Storage

Store at controlled room temperature 20°-25°C (68°-77°F). Excursions permitted to 15°-30°C (59°-86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Properly discard any unused medication after treatment completion.

Disclaimer

This information is provided for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider before starting any new medication or making changes to your treatment regimen. The prescribing physician should be aware of the patient’s complete medical history and current medications. Individual results may vary based on patient-specific factors and underlying conditions.

Reviews

Clinical studies demonstrate that Urispas provides significant symptomatic relief in patients with various urinary tract disorders. In controlled trials, patients reported statistically significant improvements in urinary frequency, nocturia, and urgency compared to placebo. Urologists consistently rate flavoxate as effective for managing bladder spasm-related symptoms, particularly noting its value in post-procedural care and chronic cystitis management. Patient satisfaction surveys indicate improved quality of life measures regarding sleep continuity and daily activities.